Open Questions
Petrov et al. achieved only moderate discrimination between ME/CFS and long COVID using composite immune markers, suggesting significant within-group heterogeneity and overlapping distributions between the two conditions (Petrov et al. 2026). If ME/CFS encompasses multiple discrete immune endotypes (CCR7-predominant defect, CD80-predominant defect, combined defect, checkpoint-dominant exhaustion), treating all patients with a single immune-restorative strategy would dilute effect sizes and risk exacerbating the wrong pathway. However, the alternative β that immune variation in ME/CFS is continuous and multidimensional with no natural clustering β is equally consistent with the data and would argue against categorical endotype-based trial designs. Single-cell immunophenotyping to identify whether discrete endotypes actually exist β and whether they predict differential treatment response β may be a prerequisite for rational immune-targeted trial design.
Key question. Can CCR7-low, CD80-low, and PD-L1-high ME/CFS endotypes be reproducibly identified, or does immune variation in ME/CFS represent a continuous multidimensional distribution with no natural clusters?
Petrovβs finding of reduced CD80 on M1-like monocytes could represent either: (a) an adaptive protective mechanism preventing chronic immune hyperactivation that would otherwise cause tissue damage, or (b) a maladaptive tolerance state that prevents viral clearance and perpetuates immune dysfunction. The distinction has profound therapeutic implications: breaking adaptive tolerance could trigger autoimmunity; failing to break maladaptive tolerance could permit ongoing pathology. Longitudinal studies tracking CD80 dynamics from acute infection through ME/CFS development are needed to resolve this question.